NCT00251797已完成1 期
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Tolerable dosage of thalidomide in combination with irinotecan
研究概览
简要总结
The study will try to answer these questions:
- What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan?
- How well does this combination work to shrink brain tumors, and how long do responses to treatment last?
- What side effects does the combination of drugs cause?
- How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
详细描述
This is a Phase I study, which means these trials are generally comparatively small and are used to determine toxicity and maximum dose. Currently, there are no "standard" treatments for Recurrent CNS Tumors. In this study, approximately 14 patients with Recurrent CNS Tumors will receive treatment with irinotecan, an intravenous drug, and thalidomide, a drug taken by mouth. Both have been approved by the Federal Food and Drug Administration as treatments for cancer, but they have not been tested together for brain cancer.
The study will try to answer these questions:
- What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan?
- How well does this combination work to shrink brain tumors, and how long do responses to treatment last?
- What side effects does the combination of drugs cause?
- How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy proven high grade astrocytomas, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, mixed oligodendroglioma.
- •Subjects are allowed to have definitive surgery and/or radiation treatment to their tumors.
- •Subjects are allowed to have previous chemotherapy for their tumors.
- •Subjects who previous diagnosed to have a low grade lesion need a second biopsy to show transformation into a high grade histology.
- •Subjects need to have radiographic or biopsy proven recurrent disease.
- •ECORT performance status 2 or lower. See appendix I.
- •Baseline laboratory values within 30 days of study entry: hemoglobin 10 gm/dl; absolute neutrophil count 1,500 cells/ml; platelet counts 100,000 cells/ml; SGOT/AST, SGPT/ALT, alkaline phosphatase, LDH 3high normal limit; total bilirubin 2.0 mg/dl.
- •Ability to provide written informed consent.
- •Age > 18 years.
- •Female patients of childbearing potential must have a documented negative serum pregnancy test within 14 days of study entry.
- •All subjects must agree to use an effective method of contraception for the duration of treatment if engaged in sexual activity where conception is possible, as specified in the STEP program for thalidomide.
排除标准
- •Therapy with any investigational drug (other than drugs available on treatment IND and used for FDA-sanctioned indications) and/or any chemotherapy regimen within 28 days of study entry.
- •Prior therapy with either irinotecan or thalidomide.
- •Oxygen saturation 90% on room air.
- •Cardiac insufficiency at New York Heart Association status 2 or greater.
- •Other active malignancies except basal or squamous cell carcinoma of the skin or in situ cervical and breast lesions.
- •History of neuropsychiatric disorder or altered mental status which prevent informed consent or compliance with protocol requirement.
- •Known hypersensitivity or allergic reaction to study drug.
- •Women at any stage of pregnancy.
结局指标
主要结局
Tolerable dosage of thalidomide in combination with irinotecan
时间窗: Unacceptable toxicities
次要结局
- Tumor response. For this study, the definition of response will include complete response, partial response and stable disease. Duration of tumor response. uality of life while on treatment(unacceptable toxicities)
研究者
研究点 (2)
Loading locations...
相似试验
终止
1 期
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase IMalignant GliomasNCT00671801M.D. Anderson Cancer Center24
已完成
1 期
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid TumorsRhabdomyosarcomasOsteosarcomaGlioblastomaNeuroblastomaNCT00132158St. Jude Children's Research Hospital19
招募中
1 期
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines TreatmentNon-Muscle Invasive Bladder Urothelial CarcinomaNCT06766266First Affiliated Hospital of Chongqing Medical University18
已完成
1 期
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)Advanced Solid MalignanciesNCT00986843Hanmi Pharmaceutical Company Limited14
已完成
1 期
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT00979563Hanmi Pharmaceutical Company Limited15